|
|
||||||||
Received November 1, 2007. Accepted for publication December 15, 2007.
Acknowledgments: The authors thank Ann V. Stewart for critical reading of the manuscript and helpful discussions.
Financial support: This work was supported by the US Agency for International Development, Project Number 936-6001, Award Number AAG-P-00-98-00006, Award Number AAG-P-00-98-00005, and the US Army Medical Research and Materiel Command.
Disclaimer: Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication, 1996 edition. Serum samples from adults participating in the Phase 1/2a malaria vaccine trial at WRAIR (ClinicalTrials.gov identifier NCT00385047) were obtained under a human use protocol approved by the Walter Reed Army Institute of Research Human Use Review Committee and the US Armys Human Subjects Research and Review Board of the Surgeon General. All volunteers gave informed consent before screening and enrollment into the study, and serum samples obtained from the volunteers were labeled with an alphanumeric code to maintain anonymity. The authors views are private and are not to be construed as official policy of the Department of Defense or the US Army.
* Address correspondence to Elke S. Bergmann-Leitner, 503 Robert Grant Ave. 3W76, Silver Spring, MD 20910. E-mail: elke.bergmannleitner{at}us.army.mil
Authors addresses: Elke S. Bergmann-Leitner, Elizabeth H. Duncan, John R. Burge, Michele Spring, and Evelina Angov, WRAIR, 503 Robert Grant Ave. 3W76, Silver Spring, MD 20910. Telephone: 301-319-9278, Fax: 301-319-7358, E-mail: elke.bergmannleitner{at}us.army.mil.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |